Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft

This publication has 19 references indexed in Scilit:

• THE MULTIMODALITY TREATMENT OF STAGE III A/B NON-SMALL CELL LUNG CANCER: The Role of Surgery, Radiation, and Chemotherapy
  Hematology/Oncology Clinics of North America, 1997
• Cancer statistics, 1997
  CA: A Cancer Journal for Clinicians, 1997
• (Hydroxymethyl)acylfulvene: An Illudin Derivative with Superior Antitumor Properties
  Journal of Natural Products, 1996
• Multidrug resistance is more than MDR1 activity
  Leukemia Research, 1995
• Characterization of illudin S sensitivity in DNA repair-deficient chinese hamster cells: Unusually high sensitivity of ercc2 and ercc3 DNA helicase-deficient mutants in comparison to other chemotherapeutic agents
  Biochemical Pharmacology, 1994
• Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
  The Lancet, 1993
• Structure-activity relationships of illudins: analogs with improved therapeutic index.
  The Journal of Organic Chemistry, 1992
• Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines
  JNCI Journal of the National Cancer Institute, 1991
• Preclinical Evaluation of Illudins as Anticancer Agents: Basis for Selective Cytotoxicity
  JNCI Journal of the National Cancer Institute, 1990
• Fungal Metabolites. The Structures of the Novel Sesquiterpenoids Illudin-S and -M
  Journal of the American Chemical Society, 1965